Advanced Recurrent Ovarian Cancer Drug Pipeline Analysis Report 2025

Around 70% of patients with ovarian cancer are likely to experience recurrence, according to the Ovarian Cancer Research Alliance. Studies show that the stage of cancer strongly influences the recurrence risk, with Stage 3 and Stage 4 ovarian cancer reported to demonstrate a 70-90% and 90-95% chance of recurrence, respectively. Advanced treatments such as antibody-drug conjugates (ADCs) and PARP inhibitors are increasingly showing positive outcomes in clinical trials. Further, accelerated approvals by regulatory bodies and the growing focus on the development of targeted therapies are poised to aid in pipeline expansion for advanced recurrent ovarian cancer in the coming years.

Report Coverage

The Advanced Recurrent Ovarian Cancer Drug Pipeline Insight Report by the publisher gives comprehensive insights into advanced recurrent ovarian cancer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced recurrent ovarian cancer. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The advanced recurrent ovarian cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from advanced recurrent ovarian cancer.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to advanced recurrent ovarian cancer.

Advanced Recurrent Ovarian Cancer Drug Pipeline Outlook

The recurrence rate for ovarian cancer is estimated to be around 80%. It is observed that cancer has a higher likelihood of recurrence if the disease is fast-growing or has reached an advanced stage at the time of diagnosis. Recurrence of ovarian cancer can occur anytime, from weeks to years after treatment. In cases of highly chemotherapy-resistant ovarian cancer, recurrence can even happen during the weeks post-treatment.

Platinum-based chemotherapies are commonly used for the treatment of advanced recurrent ovarian cancer. PARP inhibitors like olaparib, niraparib, and rucaparib are reported to show efficacy in patients with BRCA mutations. Moreover, FDA-approved Elahere (mirvetuximab soravtansine) is a promising therapy for treatment-resistant cases. Robust research efforts focused on exploring novel treatments, including vaccines aimed at preventing recurrence and innovative therapies like natural killer (NK) cell treatments, are expected to accelerate the advancement of the drug pipeline in the near future.

Advanced Recurrent Ovarian Cancer - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of advanced recurrent ovarian cancer drugs based on several segmentations including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Oligonucleotide
• Peptide
• Small molecule

By Route of Administration

• Oral
• Parenteral
• Others

Advanced Recurrent Ovarian Cancer - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase I covers a major share of the total clinical trials for advanced recurrent ovarian cancer.

Advanced Recurrent Ovarian Cancer - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the advanced recurrent ovarian cancer pipeline analysis include oligonucleotide, peptide, and small molecule. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for advanced recurrent ovarian cancer.

Advanced Recurrent Ovarian Cancer Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the advanced recurrent ovarian cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in advanced recurrent ovarian cancer clinical trials:

• Context Therapeutics Inc.
• Ascentage Pharma Group Inc.
• Verismo Therapeutics
• Valerio Therapeutics
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• AstraZeneca
• BioMimetix JV, LLC

Advanced Recurrent Ovarian Cancer - Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: BMX-001 + Paclitaxel

Sponsored by BioMimetix JV, LLC, the objective of this Phase I/II clinical trial is to investigate the efficacy and safety of the combination therapy Paclitaxel (Taxol) and BMX-001 in an estimated 27 adult patients with advanced, recurrent, metastatic ovarian or endometrial cancer.

Drug: SSGJ-707

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is conducting a Phase II clinical study aimed at evaluating the antitumor activity, safety, and tolerability of SSGJ-707 for the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The interventional study has enrolled about 80 subjects and is expected to be completed by August 2026.

Reasons To Buy This Report

The Advanced Recurrent Ovarian Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for advanced recurrent ovarian cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within advanced recurrent ovarian cancer pipeline insights.

Key Questions Answered in the Advanced Recurrent Ovarian Cancer - Pipeline Insight Report

• What is the current landscape of advanced recurrent ovarian cancer pipeline drugs?
• How many companies are developing advanced recurrent ovarian cancer drugs?
• How many phase III and phase IV drugs are currently present in advanced recurrent ovarian cancer pipeline drugs?
• Which companies/institutions are leading the advanced recurrent ovarian cancer drug development?
• What is the efficacy and safety profile of advanced recurrent ovarian cancer pipeline drugs?
• What are the opportunities and challenges present in the advanced recurrent ovarian cancer drug pipeline landscape?
• Which company is conducting major trials for advanced recurrent ovarian cancer drugs?
• What geographies are covered for advanced recurrent ovarian cancer clinical trials?
• What are emerging trends in advanced recurrent ovarian cancer clinical trials?

This product will be delivered within 3-5 business days.